Recent 8-K filings for BLGO

• March 25, 2026, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 3.02item 9.01 ◈ Equity Issuances◈ Material Agreements

  BioLargo enters $10M equity purchase agreement with Clearthink Capital Partners

  Clearthink commits to buy up to $10M of BioLargo common stock over 36 months under a Strata purchase agreement.

• March 5, 2026, 6:59 PM ET earnings materiality 0.70 negative item 7.01item 9.01

  BioLargo 2025 revenue falls 56% to $7.8M; net loss widens to $15.2M

  Total revenue dropped to $7.8M from $17.8M in 2024 due to termination of largest customer's license.

• September 25, 2025, 7:59 PM ET other material materiality 0.80 negative item 1.02item 2.06item 7.01item 9.01

  BioLargo revokes Pooph license due to $3.8M default; expects substantial impairment of $3.49M note receivable

  Pooph owed BioLargo approximately $3.8M in past-due royalties and product invoices; BioLargo revoked license on Sept 24, 2025.

• July 23, 2025, 7:59 PM ET other material materiality 0.75 neutral item 7.01item 9.01

  BioLargo mid-year update: Clyra distribution deals, Cellinity MOUs, PFAS project; Pooph sales drag

  Clyra Medical secured distribution agreements covering 6,100 hospitals, 6,300 ASCs, 2,200 wound care clinics; raised $3.3M in new capital.

• March 31, 2025, 7:59 PM ET earnings materiality 0.65 positive item 7.01item 9.01

  BioLargo reports record 2024 revenues of $17.8M, up 45% YoY; net loss narrows 6%

  Revenue $17.779M, up 45% from 2023; tenth consecutive year of revenue growth.

• November 15, 2024, 6:59 PM ET earnings materiality 0.65 positive item 7.01item 9.01

  BioLargo Q3: YTD revenue up 80% to $14.1M; net loss narrows

  Year-to-date revenue $14.1M, up 80% YoY; Q3 revenue $4.4M, up 63% YoY.

• May 15, 2024, 7:59 PM ET earnings materiality 0.65 positive item 7.01item 9.01

  BioLargo reports record Q1 revenue, positive operating cash flow of $481K

  Q1 2024 revenue $4.76M, up 28% YoY and 9% QoQ; generated $481K positive operating cash flow.

• January 22, 2024, 6:59 PM ET other material materiality 0.80 positive item 7.01item 9.01

  BioLargo Doubles Annual Revenues for Second Consecutive Year in 2023

  2023 annual revenues more than doubled 2022, driven by Pooph pet odor control product sales.

• June 9, 2023, 7:59 PM ET other material materiality 0.85 positive item 7.01item 9.01

  BioLargo Q1 revenue up 78% QoQ; Pooph generates $27M D2C sales in 18 months

  Q1 revenue up 78% QoQ and 130% YoY; net cash flow near breakeven; net loss ~$400k (non-cash).

• May 9, 2023, 7:59 PM ET other material materiality 0.65 positive item 7.01item 9.01

  BioLargo CEO projects Q1 revenue near $4M, Pooph sales driving growth

  Q4 2022 company-wide revenue grew 132% QoQ; Q1 2023 revenue expected just under $4M (3x YoY).

• March 20, 2023, 7:59 PM ET earnings materiality 0.75 positive item 7.01item 9.01

  BioLargo expects Q1 2023 revenue >4x YoY, seventh consecutive quarterly growth record

  Q1 2023 preliminary revenues expected to surpass Q4 2022 record; QoQ growth >50%.

• December 19, 2022, 6:59 PM ET other material materiality 0.60 neutral item 1.01item 3.02item 9.01 ◈ Material Agreements ×2

  BioLargo secures $10M equity line from Lincoln Park Capital; issues 1.25M commitment shares

  BioLargo entered purchase agreement with Lincoln Park Capital for up to $10M of common stock over 36 months.

• August 5, 2022, 7:59 PM ET earnings materiality 0.60 positive item 7.01item 9.01

  BioLargo Q2 2022 revenue ~$1.3M, up 185% YoY; preliminary figures

  Q2 revenue ~$1.3M, up 37% sequentially and 185% vs Q2 2021.

• May 19, 2022, 7:59 PM ET other material materiality 0.65 positive item 7.01item 9.01

  BioLargo reports record Q1 revenue of $965k; ONM subsidiary turns first profitable quarter

  Record company-wide Q1 revenue $965k (+69% YoY); ONM Environmental revenue $598k (+87%) with $13k operating profit (first profitable quarter).

• April 20, 2022, 7:59 PM ET other material materiality 0.70 positive item 7.01item 9.01

  BioLargo reports record Q1 2022 revenue of ~$900k; awarded feasibility contract for waste-to-energy plant

  Q1 2022 revenue approx. $900k, up ~60% YoY; ONM Environmental record ~$550k, engineering subsidiary ~$350k.

• April 4, 2022, 7:59 PM ET earnings materiality 0.70 positive item 7.01item 9.01

  BioLargo 2021 revenue $2.53M (+4%), net loss down 29% to $6.9M, debt cut to $0.68M

  Revenue of $2,531,000 for FY2021, a 4% increase from 2020; Q4 revenue $784,000 (+10% QoQ).

• March 8, 2022, 6:59 PM ET other material materiality 0.75 neutral item 9.01

  BioLargo unwinds 2018 Scion deal, transfers SkinDisc IP back, cancels $1.25M note

  BioLargo and Clyra assign SkinDisc IP (patents, trademark) back to Scion; Scion keeps 2M BioLargo shares.

Executive changes

Materiality & sentiment trend

Max materiality 0.85 · Median 0.50 · Most common event other_material

12 positive 2 negative 28 neutral

source · BLGO on sec.gov